KRAS-G12D抑制后EMP1+向LGR5+细胞状态转换介导转移性结直肠癌耐药
该临床前研究显示,RAS-G12D选择性共价抑制剂RMC-9945在早期肝转移结直肠癌模型中实现持久疾病控制,但在晚期转移病变中疗效减弱。治疗后的转移灶在数小时内从预后不良相关的Emp1+转录状态转变为WNT驱动的Lgr5+干细胞样状态,从而耐受RAS-G12D活性缺失,强制转换为Lgr5+状态后清除该群体可减轻转移负荷并延长生存。
要点
- RMC-9945在早期肝转移模型中持久控制疾病,晚期转移疗效减弱。
- RAS(ON)抑制剂治疗后转移灶数小时内由Emp1+转为Lgr5+干细胞样状态。
- 强制Lgr5+转换后清除该群体可减轻转移负荷并延长生存。
核心结论
- 致癌KRAS在转移性结直肠癌中主导细胞可塑性,其抑制可诱导EMP1+向LGR5+状态转换作为旁路耐药机制。
研究设计与样本
- 临床前研究,使用选择性共价RAS-G12D(ON)抑制剂RMC-9945在结直肠癌早期肝转移和晚期转移模型中进行。
主要发现
- RMC-9945在早期肝转移结直肠癌模型中实现持久疾病控制,但在晚期转移病变中治疗活性减弱。
- RMC-9945处理的转移灶从预后不良相关的Emp1+转录状态转变为WNT驱动的Lgr5+干细胞样状态,耐受RAS-G12D活性缺失。
- 细胞状态转换在RAS(ON)抑制剂治疗后数小时内发生,涉及转录因子使用转变和有限染色质重塑。
- 强制转换至Lgr5+状态后遗传清除该群体可减轻小鼠mCRC模型转移负荷并延长生存。
临床怎么用
- 提示靶向KRAS-G12D需考虑细胞可塑性旁路,联合靶向LGR5+干细胞样状态可能改善晚期转移疗效。
局限性
- 研究为临床前模型,结果需在人体临床试验中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Inhibitors of the oncogene KRAS hold promise for treating metastatic colorectal cancer (mCRC). In this study, we show that a selective, covalent small-molecule inhibitor of the active (ON) conformation of RAS-G12D, RMC-9945, exerts durable disease control in preclinical colorectal cancer models of early liver metastasis, but its therapeutic activity was diminished in the advanced metastatic disease. RMC-9945-treated metastases underwent a transition from a poor prognosis-associated Emp1+ transcriptional state to a WNT-driven Lgr5+ stem cell-like state that withstands the absence of RAS-G12D activity. This cell state change occurred within hours of RAS(ON) inhibitor treatment through a shift in transcription factor usage that involved limited chromatin remodeling. Forced conversion of metastatic cells to the Lgr5+ state through RAS-G12D inhibition, followed by genetic ablation of this population, reduced metastatic burden and prolonged survival in a mouse mCRC model. Overall, these preclinical findings demonstrate a central role for oncogenic KRAS in governing cellular plasticity in mCRC. SIGNIFICANCE: We show that inhibition of oncogenic KRAS in preclinical models of advanced mCRC exerts a limited benefit, primarily due to the reversion of tumor cells to a stem cell-like state. Our findings highlight the context-dependent effects of oncogenic KRAS mutations and underscore cell plasticity as a therapeutic opportunity. See related commentary by Eng and Yilmaz et al., p. 201.
引用
- Centonze A, Roura AJ, Novillo-Font M, et al. A Plastic EMP1+ to LGR5+ Cell State Conversion as a Bypass to KRASG12D Pharmacologic Inhibition in Metastatic Colorectal Cancer. Cancer Discov. 2026. PMID: 41128661. doi:10.1158/2159-8290.CD-25-0679
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。